GlassScriptPhysician profile
Eva B Cwynar
NPI 1558487835
$5,091.22
in general payments reported to CMS, 2019-2025
25 companies · $822 in 2025
The $822 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $317 · 2021: $704 · 2022: $727 · 2023: $1,079 · 2024: $1,109 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Education: $58.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.51 |
| Education | $58.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,610.03 | 2019-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $919.15 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Currax Pharmaceuticals LLC | $376.32 | 2021-2025 | Contrave, Nexletol, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.95 | 2019-2025 | Relistor, Trulance, Xifaxan |
| Corium, LLC | $322.67 | 2023-2025 | Azstarys |
| Pfizer INC. | $172.86 | 2021-2025 | |
| Mannkind Corporation | $161.01 | 2020-2023 | Afrezza |
| Ascendis Pharma Endocrinology INC | $129.20 | 2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $107.02 | 2021-2025 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $106.02 | 2022-2023 | Quviviq |
| Antares Pharma, INC. | $97.31 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $96.83 | 2023-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $81.68 | 2022-2023 | Tepezza |
| Ibsa Pharma INC. | $75.97 | 2024-2025 | Licart, Tirosint, Flector |
| Tolmar, INC. | $68.12 | 2025 | Jatenzo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $67.75 | 2023-2024 | Freestyle Libre 3 |
| Acerus Pharmaceuticals Corporation | $62.20 | 2021-2022 | |
| Abbvie INC. | $55.53 | 2025 | |
| Vivus LLC | $49.16 | 2023-2024 | Qsymia |
| Azurity Pharmaceuticals, INC. | $34.33 | 2023 | Adthyza |
| Astrazeneca Pharmaceuticals LP | $31.44 | 2021 | |
| Avion Pharmaceuticals | $29.66 | 2023 | NP Thyroid 60 |
| Ironwood Pharmaceuticals, INC | $27.25 | 2024 | |
| Endo Pharmaceuticals INC. | $21.89 | 2022 | |
| Cequr Corporation | $14.87 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Cwynar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.